Consider an Investigational Immunotherapy Trial for Patients with


Liver Cancer


Clinical trials are now enrolling to see if a study drug may help reduce recurrence.


937 Eligibility criteria:*


• HCC stage IB, II, IIIA, or IIIB • Patient is either a candidate for resection or ablation, and shows no evidence of disease after resection or ablation


*Additional eligibility criteria may apply.


For more information and to see if your patients may qualify, visit MerckOncologyClinicalTrials.com


Copyright © 2020 Merck & Co., Inc., Kenilworth, NJ, USA Eligibility criteria:*


• Patient has incurable non-metastatic HCC that is not amenable to transplant, resection, or ablation


• All lesions treatable with TACE


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40